pharmtech.comPharmTech Home

Search this site: This Site Include Affiliate Sites Dosage Forms | Solid Dosage/Semi-Solid Biologic Drugs Parenterals Highly Potent Drugs Inhalation Drugs Vaccines Specialty Dosage Drugs Generic Drugs Development | Biologics APIs Chemical APIs Drug Delivery Excipients Formulation Process Development Scale Up Manufacturing | Equipment Aseptic/Sterile Processing Fill-Finish Continuous Processing Process Control/PAT Packaging Supply Chain Technology Transfer Facilities Equipment & Processing Report Analytics | Analytical Instrumentation Method Development Drug Substance Analysis Finished Drug Analysis In the Lab eNews Quality/GMPs | Quality by Design QA/QC Regulatory/GMP Compliance Compendial Compliance Regulatory Authority Actions US Regulatory Watch EU Regulatory Watch Outsourcing | Analytical Services Development Services Clinical Trial Services Manufacturing Services Packaging Services Outsourcing Outlook Partnerships in Outsourcing Outsourcing Resources Pharma Marketplace Current Issue Digital Edition Archive PharmTech Europe News Events Whitepapers Webcasts Contact Us Submission Guidelines Pre-Clinical: Laying the Right Foundation Designing Commercial-Scale Oligonucleotide Synthesis Improving Solubility of Cannabinoids The Search for Transparency in Excipient Sourcing Biopharma Analysis Benefits from New Technology and Methods Managing Risk for Cell and Gene Therapy Logistics Your Online Resource to Global Suppliers Pre-Clinical: Laying the Right Foundation Designing Commercial-Scale Oligonucleotide Synthesis Improving Solubility of Cannabinoids The Search for Transparency in Excipient Sourcing Biopharma Analysis Benefits from New Technology and Methods Managing Risk for Cell and Gene Therapy Logistics Your Online Resource to Global Suppliers Pharma Trends Smoothly Through the Production Process By Florence Buscke, Pharma Insights Contributor, Sr. Global Product Manager, Schott SCHOTT has run a series of line tests to prove the efficacy and efficiency of its modular EVERIC product concepts against vial breakage. The results show a great increase in glass strength. | Sponsored Content Researchers Discover Way of Continuously and Precisely Dosing Active Agents By Pharmaceutical Technology Editors Researchers at the Technical University of Munich (TUM) have discovered a way of continuously and precisely dosing active agents using an oil-hydrogel mixture. Vectura Appoints Sharon Johnson Executive VP By Pharmaceutical Technology Editors Inhalation drug delivery company Vectura announces new organizational structure to drive innovation, customer focus, and growth. | More | Bio/Pharma News FDA and EMA Accept Biologics Application for Novartis Multiple Sclerosis Cell Therapy If approved, the therapy may become the first-choice treatment for relapsing multiple sclerosis patients and will be the first B-cell therapy that can be self-administered using an autoinjector pen. Takeda Acquires PvP Biologics for up to $330 Million Takeda announced the acquisition after the conclusion of a Phase 1 study of the investigational medicine TAK-062 (Kuma062) for the treatment of uncontrolled celiac disease. WuXi and Vir to Collaborate on Novel Coronavirus Treatment The companies are entering into a development and manufacturing collaboration for the advancement and production of human monoclonal antibodies for the potential treatment of novel coronavirus. | More | PharmTech eBook Series Regulatory Sourcebook and Reference, December 2019 In Pharmaceutical Technology 's ongoing Pharmacopoeia Compliance Series, experts explain the revision process for global and national pharmacopoeias, best practices for monitoring changes, and how to participate in revisions. Other features include FDA warning letters, building a quality culture, and essentials for DOE and QRM. View eBook Industry News FDA Ties First Drug Shortage to Coronavirus Outbreak Feb 28, 2020 With the first announced drug shortage tied to the coronavirus outbreak, FDA emphasizes urgency for monitoring drug supply chain. All-Party Parliamentary Group for Life Sciences Relaunches Feb 27, 2020 The All-Party Parliamentary Group (APPG) for Life Sciences, aimed at raising awareness of the United Kingdom’s life sciences among parliamentarians and to explore the challenges and opportunities facing the sector, was relaunched on Feb. 27, 2020. Industry Responds to UK Government’s Approach to Future Relationship with EU Feb 27, 2020 ABPI has issued a statement noting that it shares the ambition of the United Kingdom’s government, as set out in its published approach to the negotiations for the future relationship with the European Union (EU). | More | Drug Development ERS Genomics, Aelian Biotechnology in CRISPR/Cas9 License Agreement Under the agreement, ERS Genomics will license its gene-editing technology to Aelian Biotechnoloy to support its commercial functional genomic screening platform. ProBioGen, ImmunOs to Collaborate on Immunomodulators Using Transposase Technology The partners will use ProBioGen’s DirectedLuck transposase technology to support development and large-scale manufacturing of ImmunOs’ biologics. FDA Responds to Coronavirus Outbreak The agency is taking steps to monitor the supply chain and assist in the development of treatments. | More | Best Practices Human-Centered Work: How Pharma Can Move to a Blame-Free Culture As mergers continue and operations become more complex, simplifying procedures and training can prevent costly morale, quality, and compliance problems. Sharp Invests in Interactive Response Technology Solution Sharp has invested US$650,000 into enhancing its Interactive Response Technology (IRT) solution. Analysis of Sub-Visible Particles Novel analytical methods may help biologics manufacturers respond to stricter regulations on particulate matter. | More | Supplier News ERS Genomics, Aelian Biotechnology in CRISPR/Cas9 License Agreement Under the agreement, ERS Genomics will license its gene-editing technology to Aelian Biotechnoloy to support its commercial functional genomic screening platform. Eurofins DiscoverX Grants Bioassay Certification to VelaLabs Eurofins DiscoverX partners with VelaLabs to enable VelaLabs to perform highly reproducible potency lot release assays under GLP/GMP conditions. ProBioGen, ImmunOs to Collaborate on Immunomodulators Using Transposase Technology The partners will use ProBioGen’s DirectedLuck transposase technology to support development and large-scale manufacturing of ImmunOs’ biologics. | More | Top News FDA Ties First Drug Shortage to Coronavirus Outbreak Feb 28, 2020 With the first announced drug shortage tied to the coronavirus outbreak, FDA emphasizes urgency for monitoring drug supply chain. CPhI Japan Postponed Amid Novel Coronavirus Outbreak Feb 26, 2020 The decision was made after it was determined that many of the event’s largest stakeholders would be unable to travel to the conference due to the novel coronavirus outbreak. Eli Lilly Completes Acquisition of Dermira for $1.1 Billion Feb 20, 2020 Through the agreement, Lilly will expand its immunology pipeline with lebrikizumab, Dermira’s novel, investigational mAb designed to bind interleukin-13 with high affinity. | More | Bio/Pharma and Brexit Industry Responds to UK Government’s Approach to Future Relationship with EU ABPI has issued a statement noting that it shares the ambition of the United Kingdom’s government, as set out in its published approach to the negotiations for the future relationship with the European Union (EU). The Future is Bright for Post-Brexit UK Life Sciences, Notes Poll According to executive search firm Odgers Berndtson, its recent poll has highlighted that senior executives in life sciences believe there is a positive future for the United Kingdom’s sector outside the European Union. Brexit: What Happens Next for Pharma? The UK and Europe are entering a transitional period, which will involve negotiations across the board, including those on the pharma regu...